More North American biotechs, but European and Asian firms hold better assets
This article was originally published in Scrip
Executive Summary
North American biotechnology companies are more numerous, but European companies have more projects in development and Asian firms are significantly more clinically oriented. This is the top-line conclusion from Scrip’s analysis of the pipelines of some 1,765 companies which are yet to earn revenues from sales of drugs which shows that the product portfolios of Asian and European companies are significantly broader on average than those of North American companies.